Faculty Bibliography

Protamine is used routinely at our institution during arterial surgery to reverse the anticoagulant effect of heparin. Adverse fatal reactions to protamine are generally believed to be rare. However, major anaphylactoid reactions occurred in 11 of the last 1150 patients receiving this drug at our institution. Nine of these reactions occurred in 325 insulin-dependent diabetic patients (incidence, 3%), whereas only two occurred in the 825 patients not receiving insulin (incidence, 0.2%) (p less than 0.001). Ten of these reactions occurred within 10 minutes of protamine administration (15 to 35 mg), whereas one reaction occurred immediately after administration of a 5 mg test dose of protamine. Systolic blood pressure fell below 60 mm Hg in all of the 11 patients, and three patients had to be resuscitated with closed-chest massage. Initial treatment with epinephrine and steroids was successful in seven cases. Four patients required further resuscitative measures, including closed-chest massage. However, one of the patients died as a result of ventricular fibrillation resistant to treatment. Ten of the 11 patients, including the patient who died, had significant preexisting cardiac disease; six of the surviving 10 patients (60%) had perioperative myocardial infarctions and three died. Thus the total mortality rate was 36% (4/11). These data support the implication that neutral protamine Hagedorn (NPH) insulin produces an adverse reaction through immunologic presensitization of the patient. These data also show that, in the older vascular surgery population with a high incidence of significant cardiac disease, protamine reactions can be potentially lethal. Thus routine use of protamine should be avoided in diabetic patients receiving insulin

Preliminary crossmatching usually eliminates highly sensitized patients from consideration for renal transplantation. However, if the crossmatch is positive because of the presence of IgM antibody, this activity can be eliminated by treatment with the reducing agent Dithiothreitol (DTT). Successful transplantation may then be possible in patients whose crossmatch is positive due to the presence of IgM antibody. After treatment with DTT, the sera of 25 highly sensitized patients were measured for cytotoxicity against a selected panel of 40 cells. Those whose high %PRA could be attributed to blood transfusions or previous transplants did not change with DTT. Only two patients who had developed high panel reactivity, without a clear cause, had little reactivity remaining after DTT treatment of their sera. To select patients whose crossmatch might be rendered negative by DTT treatment, we developed a 'minipanel' screening protocol. Patients whose monthly PRA cells increased greater than 30% from baseline had their serum samples treated with DTT to reduce IgM. The treated sera were tested against a panel of six cells. If there was little or no cytotoxicity, it was assumed that IgM antibody was responsible for the positive crossmatches. All subsequent cadaver donor crossmatches were done with and without DTT treated sera. Five patients (2 living-related; 3 cadaver) with current crossmatches positive before, but negative after, DTT treatment continue to have functioning kidneys 3-15 months after renal transplantation. There were no hyperacute rejections. We conclude that patients with IgM antibody can be successfully transplanted if they have a negative cross-match after reduction of IgM antibody in their serum samples. A 'minipanel' helps to identify patients who will benefit from DTT treatment

This study describes a technique that facilitates lower extremity 'redo' revascularizations and that may increase the number of patients who can be revascularized. By using the distal deep femoral artery for bypass outflow or inflow, we were able to revascularize patients with no other accessible patent major thigh artery, to increase the use of autologous vein for infrapopliteal bypasses, and to avoid difficult groin reoperations. Thirty-seven patients (23 men) had various distal deep femoral revascularizations for limb salvage indications only (rest pain, ischemic ulcers, and/or gangrene). Techniques to expose the distal deep femoral artery directly are described and their uses discussed. We found that the type of bypass performed (e.g., axillofemoral or aortofemoral) determined the patency rate of the reconstruction. Placement of the origin or termination of the graft in the deep femoral artery did not appear to affect the results adversely

During the past 6 years, we have encountered 24 cases in which all major infrapopliteal arteries were occluded as determined by adequate preoperative angiography. Each patient initially had critical ischemia, 14 had a previous failed ipsilateral distal bypass, and seven had an unsuccessful lumbar sympathectomy. Instead of resorting to an amputation, we attempted to perform a bypass using patent branches of distal vessels. Of the 24 bypasses, 14 were to the lateral or medial plantar branches, three were to the deep plantar branch (plantar arch), three were to the lateral tarsal branch, and four were to unnamed branches of the proximal one third of the posterior tibial arteries (two) or anterior tibial arteries (two). All bypasses were performed with reversed saphenous vein with origins at or distal to the superficial femoral artery. Eight bypasses (four plantar and four unnamed branches) became thrombosed up to 30 months postoperatively, resulting in four below-knee amputations. Fifteen bypasses (all plantar branches) have been patent from 6 to 52 months (mean 26 +/- 13 months). The remaining patient required a below-knee amputation at 2 months despite a patent graft. These results underscore the value of this extended approach to limb salvage in situations previously believed to be indications for major amputations. Although bypasses to unnamed branches of the proximal tibial arteries did not fare well, those to the plantar branches and lateral tarsal branch resulted in excellent graft patency and limb salvage